Details for New Drug Application (NDA): 202930

NDA 202930 describes ZOLEDRONIC ACID, which is a drug marketed by Accord Hlthcare, Actavis Inc, Amneal, Apotex, Avet Lifesciences, Bpi Labs, Breckenridge, Chartwell Rx, Dr Reddys, Dr Reddys Labs Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma Farmaceutica, Hospira, Hospira Inc, Inforlife, Meitheal, Mylan Labs Ltd, Novast Labs, Sagent Pharms Inc, Shilpa, Sun Pharma Global, and USV, and is included in thirty-seven NDAs. It is available from twenty-one suppliers. Additional details are available on the ZOLEDRONIC ACID profile page.

The generic ingredient in ZOLEDRONIC ACID is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.

Summary for 202930

Tradename:	ZOLEDRONIC ACID
Applicant:	Gland
Ingredient:	zoledronic acid
Patents:	0

Pharmacology for NDA: 202930

Suppliers and Packaging for NDA: 202930

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202930	ANDA	BPI Labs LLC	54288-183	54288-183-01	1 VIAL, GLASS in 1 CARTON (54288-183-01) / 5 mL in 1 VIAL, GLASS
ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202930	ANDA	Gland Pharma Limited	68083-116	68083-116-01	1 VIAL in 1 CARTON (68083-116-01) / 5 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	EQ 4MG BASE/5ML
Approval Date:	Aug 5, 2013	TE:	AP	RLD:	No

Complete Access Available with Subscription